Charles River Laboratories Reports Mixed 2025 Results, Cautious 2026 Outlook
Event summary
- Charles River Laboratories reported a 0.8% revenue decline in Q4 2025, with full-year 2025 revenue down 0.9% to $4.02 billion.
- GAAP net loss for Q4 2025 was $(276.6) million, compared to $(215.7) million in Q4 2024, driven by non-cash intangible asset impairments.
- Non-GAAP earnings per share decreased 10.2% in Q4 2025 to $2.39, with full-year non-GAAP net income down 3.9% to $512.3 million.
- 2026 guidance projects revenue growth of (1.0)% to at least flat organically, with non-GAAP EPS expected to increase 4% to 9%.
- The company plans to divest approximately 7% of annual revenue in 2025 and estimated 2026.
The big picture
Charles River Laboratories' mixed 2025 results reflect ongoing challenges in the biopharmaceutical demand environment, particularly in the Discovery and Safety Assessment and Manufacturing Solutions segments. The company's cautious 2026 outlook highlights its focus on cost efficiency and strategic acquisitions to drive future growth. The planned divestitures and the impact of foreign exchange fluctuations remain key variables in the company's financial performance.
What we're watching
- Revenue Stabilization
- Whether Charles River can sustain the stabilization of biopharmaceutical demand and return to organic revenue growth in the second half of 2026.
- Cost Efficiency
- The pace at which the company can deliver incremental cost savings from restructuring and efficiency initiatives to support 2026 earnings growth.
- Strategic Acquisitions
- How the completed acquisition of K.F. (Cambodia) Ltd. and planned acquisition of PathoQuest SAS will impact revenue and earnings accretion in 2026.
Related topics